Journal article
Reslizumab for Poorly Controlled, Eosinophilic Asthma
Abstract
RATIONALE: Eosinophilic asthma is a phenotype of asthma characterized by the persistence of eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils.
OBJECTIVES: To evaluate the effect of the antibody to IL-5, reslizumab, in patients with eosinophilic asthma that is poorly controlled with high-dose inhaled corticosteroid.
Authors
Castro M; Mathur S; Hargreave F; Boulet L-P; Xie F; Young J; Wilkins HJ; Henkel T; Nair P
Journal
American Journal of Respiratory and Critical Care Medicine, Vol. 184, No. 10, pp. 1125–1132
Publisher
American Thoracic Society
Publication Date
November 15, 2011
DOI
10.1164/rccm.201103-0396oc
ISSN
1073-449X